Baird Medical Investment Holdings (BDMD)
NASDAQ:BDMD
Want to see BDMD full AI Analyst Report?
BDMD Stock Chart & Stats
$1.76
$0.13(1.73%)
At close: 4:00 PM EST
$1.76
$0.13(1.73%)
Day’s Range― - ―
52-Week Range$0.76 - $7.26
Previous Close$7.55
Volume323.07K
Average Volume (3M)238.60K
Market Cap
$67.21M
Enterprise Value$86.74M
Total Cash (Recent Filing)$178.32K
Total Debt (Recent Filing)$19.30M
Price to Earnings (P/E)―
Beta-0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,979,380
10 Day Avg. Volume117,298
30 Day Avg. Volume238,602
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.68
P/FCF Ratio-27.26
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-3.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustainably high gross margins provide structural pricing flexibility and a larger gross profit buffer versus peers. Over 2–6 months this supports ability to invest in R&D or absorb adverse mix shifts, helping restore operating leverage if revenue stabilizes.
Manageable LeverageDebt around 0.62x equity implies a modest leverage base and meaningful equity cushion today. That structural balance-sheet strength gives the company time to execute turnarounds or raise capital without immediate solvency pressure, assuming losses are remedied.
U.S. GAAP & SEC ReportingReporting under U.S. GAAP and SEC oversight imposes consistent disclosure and audit standards, improving comparability and access to U.S. capital markets. This structural transparency aids long-term financing and governance improvements during remediation.
Bears Say
Revenue Decline & LossesA ~29% revenue decline and a swing to deep operating losses materially weaken sustainable earning power. Over months this erodes margins, reduces pricing leverage, and undermines recovery prospects unless demand or commercial execution meaningfully improves.
Persistent Negative Cash FlowConsistent negative operating and free cash flow across multiple years highlights a structural funding gap. This forces reliance on external capital, constrains reinvestment, and raises refinancing and dilution risk if operational performance doesn't return to sustainable cash generation.
Internal Control WeaknessesDocumented material weaknesses and an auditor change signal governance and reporting risks that persist beyond a single quarter. They can increase audit costs, delay filings, impair investor confidence, and complicate capital raising or M&A while remediation continues.
Baird Medical Investment Holdings News
BDMD FAQ
What was Baird Medical Investment Holdings’s price range in the past 12 months?
Baird Medical Investment Holdings lowest stock price was $0.76 and its highest was $7.26 in the past 12 months.
What is Baird Medical Investment Holdings’s market cap?
Baird Medical Investment Holdings’s market cap is $67.21M.
When is Baird Medical Investment Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baird Medical Investment Holdings’s earnings last quarter?
Currently, no data Available
Is Baird Medical Investment Holdings overvalued?
According to Wall Street analysts Baird Medical Investment Holdings’s price is currently Overvalued.
Does Baird Medical Investment Holdings pay dividends?
Baird Medical Investment Holdings does not currently pay dividends.
What is Baird Medical Investment Holdings’s EPS estimate?
Baird Medical Investment Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baird Medical Investment Holdings have?
Baird Medical Investment Holdings has 40,979,380 shares outstanding.
What happened to Baird Medical Investment Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baird Medical Investment Holdings?
Currently, no hedge funds are holding shares in BDMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baird Medical Investment Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Baird Medical Investment Holdings
Baird Medical Investment Holdings Limited, together with its subsidiaries develops and sells microwave ablation medical devices for minimally invasive tumor treatment in China. The company's medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical Investment Holdings Limited was founded in 2012 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.61% Other Institutional Investors
99.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---